Azines as histamine H4 receptor antagonists.
Since 2000, when the histamine H4 receptor (H4R) was cloned, it has constituted an interesting target for drug development. Pharmacological studies suggest the potential utility of histamine H4R antagonists/inverse agonists in the treatment of inflammatory diseases, e.g. allergic rhinitis, asthma, atopic dermatitis, colitis, or pruritus. The first H4R ligands were non-selective compounds, but intensive chemical and pharmacological work has led to the discovery of highly potent and selective H4R antagonists (e.g. JNJ7777120, CZC-13788, PF-2988403, A-940894, A-987306). The first compound (UR-63325) has finally entered into clinical studies for the treatment of allergic respiratory diseases (completing the phase I ascending dose trial) and has been found to be safe and well tolerated. The number of scientific publications and patent applications in the H4 field is increasing annually. Among the diverse chemical structures of the H4R antagonists described a 2-aminopyrimidine scaffold is repeatedly found. This review looked at recent advances in the search for H4R antagonists as reflected in patent applications/patents and peer-reviewed publications over the last two years. The work concerns azines (mono-, di-, triazines) and their fused analogues. The chemistry and pharmacology has been described.
Department of Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Krakow, Poland.
Dorota
D
Lazewska
Katarzyna
K
Kiec-Kononowicz
D000818:Animals; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D011968:Receptors, Histamine / Q000378:metabolism*
D006573:Heterocyclic Compounds, 1-Ring; D006633:Histamine Antagonists; D011968:Receptors, Histamine